Previous 10 | Next 10 |
2024-02-18 14:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-14 14:31:52 ET Summary Sebetralstat has a compelling drug profile for the on-demand treatment of HAE attacks and could become the new standard of care in a billion-dollar market opportunity. KalVista is transitioning to a commercial company following positive Phase 3 data ...
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2023 financial results on Monday, February 26, 2024. BioCryst management will host a conference call and web...
RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of real-world use of oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic...
2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...
2024-01-08 12:34:45 ET DENVER, Colo., Jan. 8, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Aclarion Inc (NASDAQ: ACON), Spectaire Holdings Inc (NASDAQ: SPEC), Cellectar Biosciences Inc (NASDAQ: ...
2024-01-05 16:07:41 ET More on BioCryst Pharmaceuticals BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely Analyzing BioCryst's Position Amid Pharvaris' HAE Breakthrough For further details see: BioCryst announces preliminary FY23 ORLADEYO net re...
—ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)— —ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak sales— —Operating expenses expecte...
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:00 p.m. ET. Link to...
RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that data from the open-label extension (OLE) of the APeX-2 trial of oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of heredit...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...